Clinical trial

Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

NCT04272645

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2020-10-01

PhasePHASE2

Study timeline

Study start (estimated)2020-10-01Date precision: month

Registry last updated2020-07-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Prostate Cancerunresolved

Interventions

Abemaciclib 200 MGDRUG · verified · RxNorm: abemaciclib 200 MG

Atezolizumab 1200 MG in 20 ML InjectionDRUG · verified · RxNorm: 20 ML atezolizumab 60 MG/ML Injection

Abemaciclib 150 MGDRUG · verified · RxNorm: abemaciclib 150 MG

Sponsors & collaborators

University of Michigan Rogel Cancer Centerlead sponsor

Mapped research locations

BostonMassachusetts, United States1 PhiladelphiaPennsylvania, United States1 St LouisMissouri, United States1 MinneapolisMinnesota, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04272645 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.